However, our finding that PD-1 expression on circulating CD4+ T cells is prognostic for poor survival in patients with mesothelioma warrants validation in a larger cohort of patients and further investigation as a biomarker of response to immunotherapy in this patient group. Here, CD4 is linked to mesothelioma.